Long-Term Outcomes of Scleroderma Renal Crisis PDF Print E-mail
Monday, 14 December 2009 20:34
taken from http://www.flickr.com/photos/duncan/104321008/ via creative commonsIn a previous study. researchers sought to describe the medical history of a group of patients with Scleroderma Renal Crisis who had been treated with ACE inhibitors. The following is essentially a summary of that study, which was conducted by Virginia D. Steen, MD, and Thomas A. Medsger Jr., MD.

Scleroderma is a disease of unknown cause that produces fibrosis (hardening or scarring) of the connective tissue in the skin, blood vessels, and internal organs. These changes result in a tight, shiny appearance of the skin and potentially life-threatening abnormalities of the lungs, heart, digestive tract, and kidneys.

When Scleroderma involves the kidneys, it begins very suddenly with the onset of severely high blood pressure; this is called Scleroderma Renal Crisis. Without treatment, kidney failure requiring dialysis can develop and patients may die quickly. Dialysis involves connecting a person whose kidneys do not work to an artificial machine that filters waste products out of the blood.

The introduction more than 20 years ago of blood pressure drugs called angiotensin-converting enzyme (ACE) inhibitors has greatly improved the ability to treat Scleroderma Renal Crisis in the short term.

A group of researchers followed patients for up to 10 years after they had been treated with ACE inhibitors for Scleroderma Renal Crisis. Patients continued receiving ACE inhibitors after initial treatment. They also tried to identify factors that were related to better outcomes and determined patients' long-term outcomes.

Of the 145 patients studied with Scleroderma Renal Crisis, 89 had good long-term outcomes: 55 never required dialysis, and 34 (55% of those who initially required dialysis) had only temporary dialysis. Temporary dialysis lasted for an average of 8 months, and all patients were able to stop it by 18 months. Twenty-eight patients died within 6 months, and another 28 needed permanent dialysis.

This study included only patients treated at a single center, within a teaching hospital in Pittsburgh, Pennsylvania. Since patients treated with ACE inhibitors were not compared with others who did not receive this treatment, the study does not definitively prove that ACE inhibitors were the reason for the good outcomes. However, long-term outcomes were good in a substantial number of patients with Scleroderma Renal Crisis who were treated with ACE inhibitors.

For a link to Dr. Steen and Medsger's original and full article, do click here. For those of you who are logged in however, you can click on the link below to view the article directly.
 
More articles :

» Tips For Healthier Living

At the Scleroderma Care Foundation, we believe that maintaining a healthy and active lifestyle is integral to our individual ability to manage Scleroderma. This can include regular , refraining from or quitting smoking, ensuring that we stay warm,...

» The Inspirational Story of Haley Pilkington

Haley Pilkington is a remarkable singer for reasons far beyond her 14 years and the dynamic voice that so effortlessly uplifts anyone who hears her sing. Haley is a student of Deborah “Zuke” Smith, a Brett Manning Associate whose students...

» Novel Pharmaceutical Treatment for Scleroderma Discovered

A novel pharmaceutical treatment for scleroderma, comprising the administration of miR-29, has been discovered by Steffen Gay, Oliver Distler and Britta Maurer of the Department of Rheumatology at Zurich University. Scleroderma is a chronic...

» What Is Autoimmune Hepatitis?

Autoimmune hepatitis is an of the caused by an autoimmune disorder. An autoimmune disorder is one in which a person's immune system attacks his or her own body for unknown reasons. The degree of liver inflammation can range from mild to deadly.The...

» Making A Difference

, a Center for Student Missions team member, recently recounted a touching experience, in which she heard about and met someone with Scleroderma for the very first time. According to Jessica, "We don't always get to see the effect of what it is we...

» Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates...